Author/Authors :
Gholipour, Hamid Hematology Department - School of Medical Sciences - Tarbiat Modarres University - Tehran, Iran , Abroun, Saeid Hematology Department - School of Medical Sciences - Tarbiat Modarres University - Tehran, Iran , Noruzinia, Mehrdad Hematology Department - School of Medical Sciences - Tarbiat Modarres University - Tehran, Iran , Ghaffari, Sasan Tehran University of Medical Sciences - Tehran, Iran , Maali, Amirhosein Department of Medical Biotechnology - Faculty of medicine - Babol University of Medical Sciences - Babol, Iran , Azad, Mehdi Faculty of Allied Medicine - Qazvin University of Medical Sciences - Qazvin, Iran
Abstract :
Epigenetic modifications, such as methylation can occur in
multiple myeloma. SMG1is an important gene involved in cell growth which
defect in methylation of its promoter leads to reduction of cell apoptosis and
uncontrolled proliferation. In this study, we identified the methylation status of
the SMG1 gene promoter in patients with multiple myeloma.
Methods: Methylation status of SMG1 promoter in 9 patients with multiple
myeloma and 4 healthy subjects as control was determined by Methylationspecific
PCR (MSP) method.
Results: SMG1 promoter in all myeloma patients was hemi-methylated.
Meanwhile, in healthy subjects, two cases were hemi-methylated and the other
two were normal.
Conclusion: The results of this study indicated that the prevalence of SMG1
promoter methylation in patients with multiple myeloma was higher than
general population which could be important in understanding the pathogenesis
of the disease
Keywords :
Multiple myeloma , DNA methylation , SMG1 gene , Apoptosis Promoter gene
